相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Structure-Based Macrocycle Design in Small-Molecule Drug Discovery and Simple Metrics To Identify Opportunities for Macrocyclization of Small-Molecule Ligands
Maxwell D. Cummings et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Jing Yang et al.
MOLECULAR CANCER (2019)
Conformational Control of Macrocycles by Remote Structural Modification
Solomon D. Appavoo et al.
CHEMICAL REVIEWS (2019)
Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives
Jialin Duan et al.
Oncotarget (2018)
First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib
Sulman Basit et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Improving Accuracy, Diversity, and Speed with Prime Macrocycle Conformational Sampling
Dan Sindhikara et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2017)
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology
Florent Beaufils et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design
Brett R. Beno et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Discovery of a Novel Series of Thienopyrimidine as Highly Potent and Selective PI3K Inhibitors
Fangbin Han et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
Development and application of PI3K assays for novel drug discovery
Mahesh Yanamandra et al.
EXPERT OPINION ON DRUG DISCOVERY (2015)
Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma
James S. Blachly et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?
Fabrizio Giordanetto et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
Rodrigo Dienstmann et al.
MOLECULAR CANCER THERAPEUTICS (2014)
mTOR kinase structure, mechanism and regulation
Haijuan Yang et al.
NATURE (2013)
Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR
Sonia Martinez Gonzalez et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Phospshoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Discovery and Structure-Activity Relationships of a Series of Quinoline and Quinoxaline Derivatives
Nobuko Nishimura et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Macrocycles Are Great Cycles: Applications, Opportunities, and Challenges of Synthetic Macrocycles in Drug Discovery
Eric Marsault et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
Jing Yuan et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
Steven D. Knight et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
Violeta Serra et al.
CANCER RESEARCH (2008)
The exploration of macrocycles for drug discovery - an underexploited structural class
Edward M. Driggers et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Growing roles for the mTOR pathway
DD Sarbassov et al.
CURRENT OPINION IN CELL BIOLOGY (2005)
分享论文
